What are the unique effects of filgotinib compared with other drugs?

Filgotinib(Filgotinib) is an oral Janus kinase 1 (JAK1) selective inhibitor, mainly used to treat immune-related diseases such as moderately to severely active rheumatoid arthritis and ulcerative colitis. Compared with other JAK drugs such as Tofacitinib, Baricitinib and Upadacitinib, filgotinib has shown unique advantages in selectivity, tolerability and safety, so it has attracted much attention in clinical application and future development.

First of all, from a mechanism perspective, filgotinib has higher selectivity forJAK1, while its inhibitory effect on JAK2, JAK3 and TYK2 is relatively weak. JAK1 plays a leading role in regulating the signaling of inflammatory factors such as IL-6, IFN-γ, etc., while JAK2 is mainly involved in hematopoiesis-related pathways. Therefore, filgotinib selectively inhibits JAK1, which can effectively control the inflammatory response and less affect the hematopoietic system, thus reducing the incidence of blood-related adverse reactions such as anemia and neutropenia.

Secondly, in terms of safety, filgotinib shows a lower incidence of cardiovascular adverse events and venous thrombosis than other similar drugs, making it a relatively safer choice especially for middle-aged and elderly patients with cardiovascular risk factors. In addition, the overall incidence of adverse reactions of filgotinib is low. Common side effects such as infection, headache, nausea, etc. are mostly mild and reversible. Severe infections or liver function abnormalities are rare, which is particularly important for patients undergoing long-term treatment.

Furthermore, in terms of clinical performance, filgotinib has shown good response rates and durable efficacy in multiple international phase III clinical trials. After patients received filgotinib treatment, joint swelling and pain were significantly reduced, and the early onset of effect was rapid. Some patients had symptoms improved within a few weeks after treatment. It is as effective as high-dose tofacitinib in relieving symptoms of rheumatoid arthritis, or even better in some patient groups. It also shows positive promise in improving mucosal healing in ulcerative colitis.

Reference materials:https://go.drugbank.com/drugs/DB14845